Can a gout drug help lung cancer treatment reach the brain?
NCT ID NCT07485452
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding febuxostat (a gout medicine) to the standard lung cancer drug osimertinib can increase the amount of osimertinib that reaches the brain. It involves 7 adults with a specific type of advanced lung cancer who are already taking osimertinib. Researchers will measure drug levels in spinal fluid before and after adding febuxostat to see if the combination works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Maastricht UMC+
RECRUITINGMaastricht, Netherlands
-
The Netherlands Cancer Institute
NOT_YET_RECRUITINGAmsterdam, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?